The short answer
Have a pharmacist identify the valerian species and preparation before adding this root product to lofexidine. Some valerian products may impair alertness, but the name Radix et Rhizoma Valerianae alone does not establish which studied product you have.
What this answer covers
Inventory root/rhizome name has unresolved species identity. Valeriana officinalis sources apply conditionally only after that species is confirmed; other Valeriana species are not assumed equivalent.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- lofexidine
Start with the botanical name
Ask for the Latin species, root or rhizome content, extraction details and all added ingredients. The inventory’s root name does not by itself establish Valeriana officinalis or equivalence to a particular study extract.
What evidence applies if the species matches
NCCIH’s Valeriana officinalis guidance describes possible sleep-inducing effects and mental dullness, with caution about sedative co-use. Those statements should not be automatically applied to another valerian species.
A negative sleep trial is not a safety clearance
One controlled trial did not find a primary insomnia benefit for its valerian preparation. It did not study lofexidine, and it cannot prove safety of an unidentified root product. No protective spacing interval is established.
Protect alertness during withdrawal treatment
Do not drive or use machinery if drowsy, and follow the treatment team’s advice until you know how lofexidine affects you. Tell the team about alcohol and all sleep products. Contact them if sedation becomes troublesome; lofexidine should not be abruptly stopped without a plan.
Evidence and practical considerations
Side effects & toxicity
An identity check and conditional alertness precaution are appropriate; the broad exact-root sedation claim is unproven.
- Exact scope
- Inventory root/rhizome name has unresolved species identity. Valeriana officinalis sources apply conditionally only after that species is confirmed; other Valeriana species are not assumed equivalent. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- Common/root name does not establish species. No exact lofexidine combination trial; V. officinalis evidence cannot resolve the inventory identity.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Possible but unproven sleep-inducing effect; advises against use with alcohol or sedatives. Mental dullness can occur; long-term safety is uncertain.
How this applies: Applies only to a product confirmed as Valeriana officinalis root/rhizome. The inventory root name does not establish that species.
No lofexidine interaction trial. Chronic use can be followed by withdrawal symptoms when stopped abruptly.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Indirect efficacy context for tested kava and valerian preparations, not exact lofexidine safety or an unidentified valerian-root species.
Not both active botanicals together, not lofexidine co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: 2fcd907f70d19ede
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.